NorthWest Biotherapeutics Inc (NWBO)

[Diamondjim61]

You know Doc, I don't know about that.

You and Flip, RK and Senti all talk about 10,000 feet above my head.

All I know is what I was told. This whole thing has been bungled by management. They thought they knew best and still don't understand that they are the ones the screwed it up by not listening to experts. LP tried (and very admirably) to make herself the expert. But got steamrolled over by those with more experience in both biotech and the market.

Like I said, I will buy back in after the R/S. Expect there to be some type of hype before to get the PPS up and then they will sock it to you.

Then the bad news comes after that.

Best wishes to you also.

Up to about 85% of all GBM becomes mesenchymal subtype at progression. IDH1 wild type is associated with mesenchymal genotype and phenotype. Neither mesenchymal or IDH1 wild type was accounted for in this study but they have become known as prognostic indicators in relationship to DC therapies. The 100 longest lived patients have no accounted for individual characteristic that explains their longer survival. Think about this for a minute and maybe things might start to make a little more sense. Almost 90% of patients received DCVax-L and later patients seem to be doing quite a bit better than early ones. Best wishes.